- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- RX108
- Drug
- Lead sponsor
- NeuPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Torrance, California • Denver, Colorado • Decatur, Georgia + 11 more
- Conditions
- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
- Interventions
- 68Ga-R11228, 177Lu-R11228
- Drug
- Lead sponsor
- Radionetics Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Glen Burnie, Maryland • Princeton, New Jersey + 3 more
- Conditions
- Malaria
- Interventions
- BNT165c, BNT165d, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
- Conditions
- Ulcerative Colitis
- Interventions
- emvistegrast, Placebo-to-match emvistegrast
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 57
- States / cities
- Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Azacitidine, Physician Choice
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more
- Conditions
- Advanced Solid Tumor
- Interventions
- PM54, Irinotecan, Doxorubicin
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Houston, Texas
- Conditions
- Dyslipidemia
- Interventions
- niacin extended-release (NER), aspirin (ASA), aspirin placebo (ASA Pbo)
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 22 more
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- Calcitriol, Ketoconazole, Hydrocortisone
- Drug
- Lead sponsor
- Donald Trump, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Huntington Disease, Chorea
- Interventions
- Risperidone, BioStamp nPoint device
- Drug · Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
- Conditions
- Sarcoma
- Interventions
- Doxorubicin Hydrochloride, Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- ABI-009, Gemcitabine
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Hummingbird Diagnostics
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 479 participants
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- SGN-40 (anti-huCD40 mAb)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 5
- States / cities
- West Hollywood, California • Denver, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Prostate Cancer, Erectile Dysfunction
- Interventions
- sildenafil citrate and questionaires, placebo tablets and questionaires
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Breast Cancer
- Interventions
- 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Kidney Transplant Recipient
- Interventions
- Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm), Prednisone (MMF Elimination arm)
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Glioma
- Interventions
- LY2157299, Radiation, Temozolomide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • San Francisco, California • Tampa, Florida + 3 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib phosphate cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Interventions
- Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Hoover, Alabama • San Diego, California • Vallejo, California + 2 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Interventions
- Durvalumab / Tremelimumab Combination Therapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more